MG-132

Catalog No.S2619

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Cited by 42 publications:

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsNWLi[GxITnWwY4Tpc44hSXO|YYm=MUCyOUDPxE1?MofESG1UVw>?NEHFT2FKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=>NIm1NGQzPDZ7N{S5Oi=>
HL-60NUL0Z3NFS3m2b4TvfIlkKEG|c3H5MkniOFAh|ryPM3jtXlQ5KGh?NVjKRlBxTE2VTx?=M1LSb2lEPTB:MUCg{txONISzUGYzPDZ7N{S5Oi=>
SMMC-7721NVjFUWRmS3m2b4TvfIlkKEG|c3H5MXK0NEDPxE1?MV20PEBpNEXO[GJFVVORNXfiOnVPUUN3ME23MlEh|ryPNUm3WoR{OjR4OUe0PVY>
A-549NXXrPW1TS3m2b4TvfIlkKEG|c3H5NWSyT|AyPDBizszNM2Hye|Q5KGh?NXe3fnFFTE2VTx?=MVnJR|UxRDFyIN88US=>NV7qO3I{OjR4OUe0PVY>
MCF-7Mk\BR5l1d3SxeHnjJGF{e2G7M3PzOlQxKM7:TR?=MX60PEBpNWDjcVg5TE2VTx?=NXLKTnU5UUN3ME23MlMh|ryPMmL5NlQ3QTd2OU[=
SW-480NYnGcoVQS3m2b4TvfIlkKEG|c3H5MXu0NEDPxE1?Mn3uOFghcA>?M4foS2ROW09?MlXKTWM2OD12IN88US=>NWr3N2NWOjR4OUe0PVY>
NCI-H929M37NeGN6fG:2b4jpZ{BCe3OjeR?=M2jlUFEh|ryPM4DnOVczKGh?MV3EUXNQMn\ETWM2OD1yLkG3JO69VQ>?NFOyfHIzPDZ{NUC4PC=>
293TM4HNTmN6fG:2b4jpZ{BCe3OjeR?=MnLhNVAh|ryPMkXuO|IhcA>?MnL1SG1UVw>?MYXJR|UxRDJizszNNXnYT5U3OjR4MkWwPFg>
293TMY\GeY5kfGmxbjDBd5NigQ>?MV2xNEDPxE1?MWKyOEBpM324fGROW09?NHKzcVROd2SncnH0[Yx6KGmwZIXj[ZMhcGWjdD3zbI9kcyBiMUiyOFYzPTB6OB?=
HeLaNEfrd5pMcW6jc3WgRZN{[Xl?M4L4elExKM7:TR?=NXHsOZVUOSCqNE\Gb|ZFVVORM{f2WWlv\HWlZYOgVGFTWCClbHXheoFo\SCkeTDpcohq[mm2aX7nJJBzd3OnYYPvcYUh[WO2aY\peJk>NFnUO|gzPDN{MUizNy=>
MDA-MB-231MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljNNUDPxE1?Ml\IO|IhcA>?Mke4SG1UVw>?NF7XbWJKSzVyPUCuNVgh|ryPNIr6cmMzPDF3M{KwOi=>
MCF-7NHXkRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfzWYU2OSEQvF2=Mo[0O|IhcA>?NEfBeJRFVVORMXHJR|UxRTBwMUOg{txOMWOyOFE2OzJyNh?=
MCF10AM1n1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTqU|kxOSEQvF2=MXi3NkBpM1vON2ROW09?MYLJR|UxRTBwMkmg{txOM{jkTVI1OTV|MkC2
HEK-293MlHHT4lv[XOnIFHzd4F6NFrLWo4zKGGwZDCyNEDPxE1?MY[yJIg>M{fJUWROW09?M3PHZ2lvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?=MVqyN|U1ODd7MB?=
Calu6NIr4clZHfW6ldHnvckBCe3OjeR?=NWftb2xkOTBizszNM{K2VVE5KGh?M{fwNWROW09?NXTDS3g4W2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I>NGexNJkzOzVyNkS4Oi=>
IFN-gamma-induced RAW264.7Mn\JSpVv[3Srb36gRZN{[Xl?MXnEUXNQNIDyflZKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5yN{eg{txOMXKyNlI4PzJ5Nx?=
IPC227FM2T5TWN6fG:2b4jpZ{BCe3OjeR?=M1PCNlEh|ryPM{LPT|Q5KGh?M2DrNGROW09?MUDJR|UxRTBwMEe3JO69VQ>?MkfINlE6OjR3Mki=
Hepa-1c1c7MmqxSpVv[3Srb36gRZN{[Xl?M4PSXlI2KM7:TR?=NYLWcYhZPiCqMk\ZSG1UVw>?NWn0[m5TUW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>?NHnJSoMzODN7MkW0OC=>
COS-7NHjtWIFEgXSxdH;4bYMhSXO|YYm=NWjpVXBJOTBizszNMmDMSG1UVw>?Mn3CTWM2ODxzMDFOwG0>MXKxPFA5QDB7Nx?=
HuH-7MYTDfZRwfG:6aXOgRZN{[Xl?NW[xSYp1OTBizszNMk\qSG1UVw>?MnvETWM2ODxzMDFOwG0>NIewTHIyQDB6OEC5Oy=>
OCI-Ly3M3rZZWZ2dmO2aX;uJGF{e2G7NXHqUFEzOTBizszNxsA>M2LVc|QhcA>?MkjDSG1UVw>?NXnUcotrUW6mdXPld{BpfW2jbjDJb4FxeGGEYXzwbIEhe3SjYnnsbZpifGmxbjD3bZRpKEWFNUCgc4YhOSEQvF2=M3PzeVE5ODJ2MUGz
A2780 cDDPNEn2OoFCeG:ydH;zbZMhSXO|YYm=NHTKWlEzPCCqMVjEUXNQNIjWTZZKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnjpZol1cW6pIGDUSW4h\GWpcnHkZZRqd25?MkHMNVc3QDRyMUi=
LPS-stimulated RAW264.7 cellsNI\jWFNHfW6ldHnvckBCe3OjeR?=NYTEXnFVTE2VTx?=NXv4WZA5UW6qaXLpeJMhVkZva3HwdIFDKESQQTDibY5lcW6pNGHud2UyPzRyN{K3Oy=>
PC12MWTGeY5kfGmxbjDBd5NigQ>?Mk\1NVAxKM7:TdMgNYTDXXBjOjRiaB?=NH\ER|NFVVORNHu3R|JKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6M3z4ZVE4OTV6NEW0
PC3M3vZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHsNlAh|ryPNFfnVZU1QCCqM1PMe2ROW09?MkDtTWM2OD1yLk[g{txOMWixOlY5PjV|Nx?=
LP-1NHvuboVCeG:ydH;zbZMhSXO|YYm=MnX1N|AxKG6PNWjlc4R[OjRiaB?=MUjEUXNQNG\I[4dKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnPy[YF{cW6pIHPs[YF3\WRiUFHSVEBt\X[nbDDhcoQhemWmdXPpcochVWOuLUGgdJJwfGWrbjDs[ZZmdA>?MnfjNVU6PTh3OEm=
ES6NWK5[HZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rkSmlEPTB;MD6wNVMxPiEQvF2=MWPTRW5ITVJ?
A101DNGjyXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HrNWlEPTB;MD6wN|I4QSEQvF2=M4LJ[HNCVkeHUh?=
OCUB-MMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\mT457UUN3ME2wMlA{PzN5IN88US=>NXjIcZVPW0GQR1XS
LB2518-MELMoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwMEO3OkDPxE1?MmX1V2FPT0WU
SH-4M331[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjsTWM2OD1yLkC0N|Eh|ryPMoXJV2FPT0WU
KNS-42NH3aWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzuTWM2OD1yLkC0OFQyKM7:TR?=MWPTRW5ITVJ?
DSH1M3T3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXjVXFSUUN3ME2wMlA2Ojh7IN88US=>NED4d5pUSU6JRWK=
NTERA-S-cl-D1MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLjUnJKSzVyPUCuNFU4PzJizszNNFr0[ohUSU6JRWK=
D-542MGNIX6emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTBwMEW5OVch|ryPNIXwem1USU6JRWK=
KS-1Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorGTWM2OD1yLkC2OFU5KM7:TR?=M3zmOXNCVkeHUh?=
BL-41M{HjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTBwME[5OFch|ryPM1jkU3NCVkeHUh?=
LXF-289MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVy5NIdJUUN3ME2wMlA4ODZ4IN88US=>M2\3NXNCVkeHUh?=
D-247MGNEfyU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTBwMEeyNFkh|ryPNFj3UHFUSU6JRWK=
MMAC-SFNYLiXI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T3XWlEPTB;MD6wO|I3QCEQvF2=NEflPIxUSU6JRWK=
CP66-MELMlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\JTWM2OD1yLkC3OUDPxE1?NECxeVJUSU6JRWK=
LB771-HNCNFjjRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXqTGxKSzVyPUCuNFgxOzZizszNMVHTRW5ITVJ?
no-10MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwMEi5NFkh|ryPMYfTRW5ITVJ?
A388NH36WZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moj0TWM2OD1yLkC5NFY2KM7:TR?=M1rsPHNCVkeHUh?=
OPM-2NFS4b45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnviTWM2OD1yLkGwOFc1KM7:TR?=MkD2V2FPT0WU
OVCAR-4NYXTZWs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PNXGlEPTB;MD6xNFk{QCEQvF2=NVLJXYhSW0GQR1XS
HOP-62NETNVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTBwMUC5OFkh|ryPNFPSS2NUSU6JRWK=
ML-2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwMUG4NFYh|ryPNHHWRllUSU6JRWK=
UACC-257NXjnXYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzqemliUUN3ME2wMlEyQTJ5IN88US=>MoTBV2FPT0WU
NEC8NG[xblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnK3TWM2OD1yLkGxPVk2KM7:TR?=NXjZTHJoW0GQR1XS
ONS-76NVXFcWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWS0RoNIUUN3ME2wMlEzQTN3IN88US=>NW[ySmx3W0GQR1XS
KE-37M2XnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTPclBJUUN3ME2wMlE{Ojd6IN88US=>NXz3OWw1W0GQR1XS
HT-144NWSw[oF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFq1W4RKSzVyPUCuNVM5QTVizszNM{jwXnNCVkeHUh?=
LB2241-RCCNGHSdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlyxTWM2OD1yLkG0NlQ4KM7:TR?=NFmwPVRUSU6JRWK=
TE-5NED6fFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFm3UotKSzVyPUCuNVQzPzhizszNMoHzV2FPT0WU
KINGS-1NIXM[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV71[|FOUUN3ME2wMlE1PzlizszNMUHTRW5ITVJ?
NCI-H69MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rNV2lEPTB;MD6xOVE1OSEQvF2=M2\heXNCVkeHUh?=
CAS-1MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7adWcyUUN3ME2wMlE2PDh{IN88US=>NHzLOG5USU6JRWK=
D-263MGM1[yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\nOGlEPTB;MD6xOlAxPiEQvF2=NFrXVFFUSU6JRWK=
A253MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLoN|FQUUN3ME2wMlE3OTJ6IN88US=>MVPTRW5ITVJ?
PF-382MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwMU[3NFYh|ryPNYDGO3hWW0GQR1XS
CESSM4T6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnVcHFKSzVyPUCuNVcxPiEQvF2=M32yeXNCVkeHUh?=
MZ2-MELMlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;VPWlEPTB;MD6xO|U2QSEQvF2=NYnjWplxW0GQR1XS
HELMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV31eolJUUN3ME2wMlE5PTF5IN88US=>MWDTRW5ITVJ?
D-392MGNGHxWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDQUJRwUUN3ME2wMlE6OTF3IN88US=>Moj4V2FPT0WU
SK-LMS-1M17nV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDm[JpKSzVyPUCuNVk{ODNizszNM1zifnNCVkeHUh?=
GI-ME-NNFHCNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XVNWlEPTB;MD6xPVMxPiEQvF2=NWDITI9uW0GQR1XS
LB831-BLCMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M120eGlEPTB;MD6xPVM1KM7:TR?=NVrVXYh2W0GQR1XS
DU-4475NXjw[lZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnyUmZPUUN3ME2wMlE6PjV6IN88US=>MV\TRW5ITVJ?
IST-SL1M3m3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4K1fmlEPTB;MD6yNFA6PCEQvF2=NIjtPVZUSU6JRWK=
GAKMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXQVpRYUUN3ME2wMlIxPTN2IN88US=>MmPNV2FPT0WU
EW-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzMRVlKSzVyPUCuNlExPDdizszNNYLOSZp2W0GQR1XS
LAMA-84M4HUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDhXI1KSzVyPUCuNlE5PTFizszNNF;pV2FUSU6JRWK=
SK-UT-1NIrrRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37BWWlEPTB;MD6yNlA1QSEQvF2=MkHRV2FPT0WU
VA-ES-BJMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojNTWM2OD1yLkKyNlU4KM7:TR?=MmD6V2FPT0WU
ACNNIDGc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTBwMkK2N|gh|ryPNHy0elRUSU6JRWK=
SK-PN-DWMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDQTWM2OD1yLkKzNVkh|ryPM1zx[HNCVkeHUh?=
HD-MY-ZNXPNcnlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\DTmN7UUN3ME2wMlI{OzB|IN88US=>NU\LeZo5W0GQR1XS
LB373-MEL-DNX;Q[5ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\jTWM2OD1yLkK0NVk5KM7:TR?=NFTuZ4pUSU6JRWK=
COLO-829NXTpZW93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF2xepdKSzVyPUCuNlQzPTdizszNMYLTRW5ITVJ?
ES8NWL2c281T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGO2flhKSzVyPUCuNlQ4PjNizszNMYHTRW5ITVJ?
RXF393MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX3bYdnUUN3ME2wMlI2ODF3IN88US=>NEDXbHlUSU6JRWK=
TK10NFHYOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjuTWM2OD1yLkK1OFM2KM7:TR?=NWjxUnBQW0GQR1XS
LOUCYMoj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMkW0OVYh|ryPMmGwV2FPT0WU
MZ7-melM32wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGG3R49KSzVyPUCuNlY{PzRizszNMlfHV2FPT0WU
CP67-MELMnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fze2lEPTB;MD6yOlc{KM7:TR?=NIThT|VUSU6JRWK=
C2BBe1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jKRWlEPTB;MD6yO|kxPyEQvF2=MmDBV2FPT0WU
K052M3Xtcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vnfmlEPTB;MD6yPFk6KM7:TR?=MWnTRW5ITVJ?
MOLT-16NGXydZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTBwMkm1NlQh|ryPMnPuV2FPT0WU
KNS-81-FDMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2W2NmlEPTB;MD6zNFMzOyEQvF2=M4P2cHNCVkeHUh?=
CMKNWPIO4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPzeYhsUUN3ME2wMlMyOTJizszNM4HYTHNCVkeHUh?=
LAN-6MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTBwM{GzJO69VQ>?MWDTRW5ITVJ?
KLENXLZXVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVf3UnY3UUN3ME2wMlMyOzB4IN88US=>NUHsSopDW0GQR1XS
NCCITNV\YeFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonPTWM2OD1yLkOxO|g{KM7:TR?=MV\TRW5ITVJ?
HHMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDDXnhxUUN3ME2wMlMzQDl5IN88US=>M{j3eHNCVkeHUh?=
TE-8NWfOS4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPY[WxPUUN3ME2wMlM1Ojd7IN88US=>NU\pR5lIW0GQR1XS
GDM-1M3H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGL0N41KSzVyPUCuN|UyODRizszNMl3BV2FPT0WU
NCI-H747MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf6cnhzUUN3ME2wMlM4OTB|IN88US=>M4LiO3NCVkeHUh?=
NCI-H1092NWqxR2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fUVGlEPTB;MD6zPFg1PCEQvF2=NFLaSXhUSU6JRWK=
8-MG-BAMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;vcVJKSzVyPUCuN|k5OzdizszNMVXTRW5ITVJ?
NB17NEjLcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXreZFKSzVyPUCuOFI6PyEQvF2=M2jpS3NCVkeHUh?=
LC4-1M4rkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17sN2lEPTB;MD60N|YxPyEQvF2=NHOxbGNUSU6JRWK=
TE-1NXXjT4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIr2T|BKSzVyPUCuOFUyOTlizszNMXfTRW5ITVJ?
KALS-1NGHKT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTBwNE[1PFQh|ryPMkHWV2FPT0WU
CCRF-CEMMlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2i5XmlEPTB;MD60O|Y4PCEQvF2=NIXsbHpUSU6JRWK=
OS-RC-2MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO1TWM2OD1yLkS3PVczKM7:TR?=NGTidGVUSU6JRWK=
A704M2fVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnQZVlxUUN3ME2wMlQ5Pjl{IN88US=>Ml;LV2FPT0WU
BB49-HNCNGHG[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4K3TWlEPTB;MD60PVA6PiEQvF2=NWPKRpVpW0GQR1XS
EVSA-TMmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrRTWM2OD1yLkS5PVEyKM7:TR?=MV3TRW5ITVJ?
Mo-TM2TqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\qfVVlUUN3ME2wMlUyPzZ{IN88US=>NHf0ZVBUSU6JRWK=
MONO-MAC-6NELNTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PKb2lEPTB;MD61N|YyOSEQvF2=NEXZZW5USU6JRWK=
BB65-RCCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLufWlrUUN3ME2wMlU3QDFzIN88US=>MYrTRW5ITVJ?
NCI-H1882NHnheWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkGyTWM2OD1yLkW5NFM3KM7:TR?=NXHORY4zW0GQR1XS
TE-9MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULTW5piUUN3ME2wMlYyODN|IN88US=>NIHTdFhUSU6JRWK=
NCI-H2126M2fNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVi1cYJ[UUN3ME2wMlYzPjZ7IN88US=>NWL3RpJKW0GQR1XS
SF268M3LSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV64em5HUUN3ME2wMlY2PjRzIN88US=>NUHI[opGW0GQR1XS
SW872M{fheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jETmlEPTB;MD62OVczQSEQvF2=NH;4bohUSU6JRWK=
LS-513NH3rfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTBwNk[3OVEh|ryPNXHxU3FNW0GQR1XS
NCI-H1355MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XhUmlEPTB;MD62PFYyQSEQvF2=MYfTRW5ITVJ?
BL-70NIS2[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHIUYtpUUN3ME2wMlY6Ozh6IN88US=>NY\lTpZyW0GQR1XS
NCI-SNU-5MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXESmI6UUN3ME2wMlY6PTR3IN88US=>M{DoV3NCVkeHUh?=
SNU-C2BNWrab2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTBwN{C3N|kh|ryPM2rKN3NCVkeHUh?=
GB-1NV;Hb21lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH32NnNKSzVyPUCuO|IyOjRizszNNXXSbHZXW0GQR1XS
CTB-1MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnSSnE{UUN3ME2wMlc4QTV3IN88US=>MkPFV2FPT0WU
BeckerNUL0OlhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTGZ41iUUN3ME2wMlc6PjJzIN88US=>M2P0SXNCVkeHUh?=
KM12NIXHSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;oOHJtUUN3ME2wMlg2PDZ4IN88US=>NGmzc5ZUSU6JRWK=
ES7MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXmXoxlUUN3ME2wMlg6PjVizszNMl24V2FPT0WU
COLO-684M1XGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITKdJFKSzVyPUCuPVA3PThizszNMlLIV2FPT0WU
HCC2998NGntdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwOUO4OVQh|ryPM3q0SHNCVkeHUh?=
TE-10MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXNTWM2OD1yLkm2OFMh|ryPNH7lcHdUSU6JRWK=
SF126M3v5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUO2XotDUUN3ME2wMlk5QTdzIN88US=>NU[4[Ig1W0GQR1XS
EKVXNIG5TpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;3eY9KSzVyPUGuNFM1PDJizszNMlTIV2FPT0WU
KARPAS-45MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3aeWdWUUN3ME2xMlA1ODF4IN88US=>NIXwWXJUSU6JRWK=
KGNNGfZe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnGbXh3UUN3ME2xMlA2ODR3IN88US=>M{KxU3NCVkeHUh?=
ES1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7VW25vUUN3ME2xMlA4QTJzIN88US=>MV\TRW5ITVJ?
L-540NWXm[IVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTHTWM2OD1zLkGxPFM6KM7:TR?=MY\TRW5ITVJ?
KURAMOCHIMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;j[YpYUUN3ME2xMlEzOzd2IN88US=>NH7GcI1USU6JRWK=
LU-65MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFwMUK3OVMh|ryPM123VnNCVkeHUh?=
MFH-inoMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPMeGZDUUN3ME2xMlE4PTBzIN88US=>M3fkZ3NCVkeHUh?=
NCI-H23NY\5RWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPQR|BKSzVyPUGuNlA1OSEQvF2=NGPCZldUSU6JRWK=
IA-LMMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTFwMkSxNVYh|ryPNGXJWYRUSU6JRWK=
PSN1NX:3cnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTFwMkewNVYh|ryPM1XMXHNCVkeHUh?=
NCI-H719MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLqXFNKSzVyPUGuNlc1OTFizszNMl7yV2FPT0WU
SW684NF25SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PNOWlEPTB;MT6yPFY2QSEQvF2=M2PJb3NCVkeHUh?=
HCE-4NYPvNHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLoTWM2OD1zLkOwNlIyKM7:TR?=NUTpcoJsW0GQR1XS
EW-16M3XFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnzTWM2OD1zLkOxN|Q4KM7:TR?=NXXqN|R[W0GQR1XS
NCI-H128NFzle3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDLSpBKSzVyPUGuN|U5OTRizszNM4ez[XNCVkeHUh?=
HC-1M1\jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTITWM2OD1zLkO4NVch|ryPMYPTRW5ITVJ?
IST-MES1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXK1NoJXUUN3ME2xMlQxOjB6IN88US=>NVvRfFB2W0GQR1XS
RajiMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFwNEG4OUDPxE1?MUfTRW5ITVJ?
DMS-114M2XqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPTeGoyUUN3ME2xMlQ1PTN7IN88US=>MWPTRW5ITVJ?
GI-1NVHYV5Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIL5VGlKSzVyPUGuOFcyOzFizszNMoLpV2FPT0WU
NCI-H2081Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nGfmlEPTB;MT61OVE6PiEQvF2=NHv3NJpUSU6JRWK=
LC-1FMoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnaTWM2OD1zLkW1NVk5KM7:TR?=MnS4V2FPT0WU
NCI-H2227NIDwTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTFwNkG1OlEh|ryPMoHEV2FPT0WU
D-502MGMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTFwNkeyNVEh|ryPM17wW3NCVkeHUh?=
NCI-H2141NWPDVpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXZRVJuUUN3ME2xMlY4OzF5IN88US=>Ml;JV2FPT0WU
LS-411NNHLyTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\XNGlEPTB;MT62PVgxPyEQvF2=MWPTRW5ITVJ?
SU-DHL-1MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTFwN{GyPFEh|ryPM1HnfnNCVkeHUh?=
BB30-HNCMkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHlcIJKSzVyPUGuO|I3QDVizszNM13LeHNCVkeHUh?=
TE-15MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrPTWM2OD1zLkmyN|c{KM7:TR?=Mn;uV2FPT0WU
JVM-3NXLTeopXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEP3UHlKSzVyPUGuPVM6ODRizszNM{TGbHNCVkeHUh?=
IST-SL2MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXOTWM2OD1{LkCxNlUzKM7:TR?=NWHTN|A6W0GQR1XS
EW-18M4nPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\PTWM2OD1{LkCyN|M4KM7:TR?=MVXTRW5ITVJ?
DJM-1NI\2TVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTzbox1UUN3ME2yMlAzPTV{IN88US=>NFvRb|NUSU6JRWK=
no-11NFT2TYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJwMEOxNFQh|ryPM17rOnNCVkeHUh?=
QIMR-WILMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvLTWM2OD1{LkG2O|YzKM7:TR?=NUDtVZBpW0GQR1XS
MC-CARMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnL4TWM2OD1{LkKyPVUh|ryPM4PCNXNCVkeHUh?=
KM-H2NWHEdoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHrVFRKSzVyPUKuNlkxPDNizszNNEPJNmtUSU6JRWK=
ECC12MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PSdWlEPTB;Mj6zO|k1KM7:TR?=MofPV2FPT0WU
HCE-TNIr3N2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJwNES4PFMh|ryPMkfXV2FPT0WU
MFM-223NGH5e2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHyXmRKSzVyPUKuOVA5PzFizszNNU\yPXdEW0GQR1XS
SW982MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;X[41PUUN3ME2yMlUyPDhizszNMVLTRW5ITVJ?
KG-1NELaRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\1b2lEPTB;Mj64PFc6OSEQvF2=NFW4N2pUSU6JRWK=
ES4M4O4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HCUmlEPTB;Mz6wOlEyOSEQvF2=NVHsV2JyW0GQR1XS
SCC-3M2DTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\uNHpJUUN3ME2zMlExQDR6IN88US=>Mlr0V2FPT0WU
RH-1NY\XdJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHSVpdKUUN3ME2zMlM5PzR6IN88US=>M2TsenNCVkeHUh?=
NCI-H748NFfrXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTNwNESyOlYh|ryPNEPuNmxUSU6JRWK=
HCC2218MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2P1d2lEPTB;Mz60Olk{PyEQvF2=M4rUZXNCVkeHUh?=
MEG-01MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;3fJNKSzVyPUOuOVk3QCEQvF2=MlvZV2FPT0WU
NB12NV;ZdoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjXW4VPUUN3ME2zMlU6QDh6IN88US=>NVXSUXRlW0GQR1XS
SNB75MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTNwNkCxNFMh|ryPM4W3cnNCVkeHUh?=
KMS-12-PENILGUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTNwNke3NlMh|ryPNEnvTohUSU6JRWK=
SKM-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTNwN{GzO|Yh|ryPMYjTRW5ITVJ?
COLO-320-HSRNWLsNHpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHHOWFKSzVyPUOuO|U3OzRizszNMo\qV2FPT0WU
NKM-1M4PP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfiV2J[UUN3ME2zMlc4Ozd6IN88US=>MnzMV2FPT0WU
TE-6MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHzT3VKSzVyPUOuPVQ2PjFizszNMXLTRW5ITVJ?
D-336MGMorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jMV2lEPTB;ND6wNVE3PiEQvF2=MnG5V2FPT0WU
NCI-H1650MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fwfGlEPTB;ND6xOVc6PyEQvF2=MWPTRW5ITVJ?
ES3MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nYN2lEPTB;ND6zNlgzPCEQvF2=NGnNO2RUSU6JRWK=
YTMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTRwM{W0NlQh|ryPNX\kOVJoW0GQR1XS
ES5MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7qR2FJUUN3ME20MlQxOjV3IN88US=>MWrTRW5ITVJ?
LB647-SCLCNX34UJNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTRwNU[zNFgh|ryPNVzsVGxNW0GQR1XS
HAL-01MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDWbIRKSzVyPUSuOVcxOzRizszNMmTTV2FPT0WU
LP-1MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mln2TWM2OD12LkeyN|cyKM7:TR?=NGfTS2RUSU6JRWK=
BC-1M{OweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTVwMEC0OFch|ryPNET5TWhUSU6JRWK=
EB-3NHjZO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\zTWM2OD13LkCzNFQyKM7:TR?=NIDDdnRUSU6JRWK=
GT3TKBMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWi5fFJ4UUN3ME21MlE4PjZ{IN88US=>MWjTRW5ITVJ?
NCI-H209NVyzcZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XCXmlEPTB;NT6xPVM2OiEQvF2=NXmwWGk1W0GQR1XS
BT-474M3nmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTVwMkOxNFIh|ryPMoWyV2FPT0WU
RKOMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIftU4hKSzVyPUWuNlM1OjJizszNMoHSV2FPT0WU
SIMAMn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTVwM{C3OlUh|ryPNXjtZ5BNW0GQR1XS
RLM17vWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTUTWM2OD13LkO3OVQyKM7:TR?=MWrTRW5ITVJ?
GCIYMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1WxOWlEPTB;NT60O|I{PiEQvF2=NGriUpFUSU6JRWK=
Calu-6Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXhTWM2OD13Lk[yNkDPxE1?MkD2V2FPT0WU
ALL-POMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4riO2lEPTB;NT62N|c6PSEQvF2=NF72bZZUSU6JRWK=
ARH-77MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWW2eVZ4UUN3ME21MlY4ODh5IN88US=>NFLXO49USU6JRWK=
A4-FukNGjLbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fYNGlEPTB;Nj6wPFEyQCEQvF2=NFjFNoJUSU6JRWK=
NCI-H1581NWfXR5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTZPFhKSzVyPU[uNlM5PDlizszNNGftSFhUSU6JRWK=
HUTU-80NFfQN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfWXo9UUUN3ME22MlM3QDl5IN88US=>MY\TRW5ITVJ?
TGWM3fyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fwcmlEPTB;Nj60OVU6OyEQvF2=MXzTRW5ITVJ?
SK-N-FIM2ruTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2f6NGlEPTB;Nj60OVg2PCEQvF2=MkDEV2FPT0WU
U-266NVjFcpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvaRYFKSzVyPU[uOVE6OjZizszNNXXvc2o1W0GQR1XS
EM-2M4TyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDlN2F4UUN3ME22MlY4ODl7IN88US=>NXftUIdFW0GQR1XS
NMC-G1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITxUYxKSzVyPU[uO|E5QTVizszNNI\U[opUSU6JRWK=
KASUMI-1NGPOUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTZwOES3PFch|ryPNGHLfW5USU6JRWK=
NALM-6MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjMTFdRUUN3ME22Mlg3PzV2IN88US=>NX2yRmVqW0GQR1XS
OCI-AML2NV\DUIExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLvWlB1UUN3ME23MlAxOzJ4IN88US=>MXPTRW5ITVJ?
SHP-77NUHOSFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTdwMkK0N{DPxE1?M2e2PHNCVkeHUh?=
NOMO-1NVTmfIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H2UGlEPTB;Nz6yOFI2PCEQvF2=NIX5NolUSU6JRWK=
SK-N-DZNEfpeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33GWGlEPTB;Nz63NVA5QSEQvF2=MXLTRW5ITVJ?
LB1047-RCCNVjDeIw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTdwN{KyN|Eh|ryPMmHQV2FPT0WU
MZ1-PCNFL1eGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUC5bFl5UUN3ME23Mlg3PTV6IN88US=>NH7zZZVUSU6JRWK=
NB10NIjJZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{D0O2lEPTB;Nz65PVU2PiEQvF2=NH[0S45USU6JRWK=
RL95-2M{D3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17UdWlEPTB;OD6xNFg1OiEQvF2=M{\Je3NCVkeHUh?=
OMC-1Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTjTWM2OD16LkWyNVkyKM7:TR?=MX3TRW5ITVJ?
D-283MEDMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRThwOUG3NVkh|ryPMkfYV2FPT0WU
MC116NVXHZXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlL2TWM2OD16Lkm3PVQh|ryPM3nGWnNCVkeHUh?=
SJSA-1M1;kZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjITWM2OD17LkC5NFkyKM7:TR?=NV\zTpFkW0GQR1XS
JiyoyeP-2003Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fKcGlEPTB;OT6yPVMyPyEQvF2=NUHJVnNwW0GQR1XS
IST-MEL1NHHZbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTlwN{SxPVgh|ryPM1PzUHNCVkeHUh?=
CTV-1NXmxN29yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLOdnRKSzVyPUGwMlA6PzlizszNNH7XV3VUSU6JRWK=
NH-12Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFyLkK0N|Mh|ryPMY\TRW5ITVJ?
CA46NFTMXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPDTXZKSzVyPUGwMlM3OSEQvF2=MWPTRW5ITVJ?
NCI-SNU-1Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;rXpZQUUN3ME2xNE41QTZ7IN88US=>NY\5R2xpW0GQR1XS
SCLC-21HMnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\6O4tKSzVyPUGwMlY2QTZizszNNFrUXohUSU6JRWK=
EC-GI-10MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnUTWM2OD1zMD63NFMyKM7:TR?=NWTzfYRIW0GQR1XS
SRNXn0RngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrkPHZKSzVyPUGxMlAyQDVizszNMljrV2FPT0WU
NCI-H1648NEXrNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHriSYRKSzVyPUGxMlA6PjVizszNNInxUXNUSU6JRWK=
TGBC1TKBNGnzRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIH6ZYFKSzVyPUGxMlQyODJizszNNX\WPJVTW0GQR1XS
EW-11MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDuSWRKSzVyPUGxMlUyQDZizszNNHP5cXFUSU6JRWK=
SK-MM-2NHTxSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTFzLkiwOlEh|ryPNXqxV3lwW0GQR1XS
NCI-H524M3rpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LCTmlEPTB;MUGuPVgzOiEQvF2=MY\TRW5ITVJ?
NOS-1NEH0d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3pdYNwUUN3ME2xNk4xOzR3IN88US=>MnKwV2FPT0WU
AM-38MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH:5RWpKSzVyPUGyMlU3OzNizszNM4HmO3NCVkeHUh?=
A498MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTF{LkewOlkh|ryPMV3TRW5ITVJ?
KARPAS-422NUPkXIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoKwTWM2OD1zMj63OFk3KM7:TR?=NYSwSVZTW0GQR1XS
LU-139MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4ThSmlEPTB;MUKuPVAzPiEQvF2=M1;Z[XNCVkeHUh?=
COR-L88MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\MZZpKSzVyPUGyMlk{QDJizszNNVzlWlFuW0GQR1XS
K5M2\MSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnoe49IUUN3ME2xNk46PDZ{IN88US=>NW\1OWNZW0GQR1XS
NB13NE\abo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTF{Lkm3PFMh|ryPNV2yOmJIW0GQR1XS
MRK-nu-1M3fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\JcZNGUUN3ME2xN{4yQTVizszNNYHHTFRVW0GQR1XS
MHH-NB-11M{O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTF|LkK5NFIh|ryPM1LmTHNCVkeHUh?=
KU812MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;zSGlEPTB;MUOuOlEzPCEQvF2=MYnTRW5ITVJ?
TE-12NILzPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTF|Lk[5PVQh|ryPMWXTRW5ITVJ?
NCI-N87M1HqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfOXWxHUUN3ME2xN{44OzZizszNM1T4OnNCVkeHUh?=
EB2Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mln0TWM2OD1zMz64OVA2KM7:TR?=NGjmfmdUSU6JRWK=
DBNH3SbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvrTWM2OD1zMz65PFg2KM7:TR?=NVfUdJVVW0GQR1XS
697NVjHeHhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTF2LkS1NVEh|ryPNXjhV4JbW0GQR1XS
MSTO-211HNUC1d5N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PWbmlEPTB;MUSuO|Q1QCEQvF2=MkXMV2FPT0WU
JVM-2MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\Yb2lEPTB;MUSuO|c{PSEQvF2=NWewbnVwW0GQR1XS
COLO-824M1XDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTF2Lke5PVQh|ryPNVjjflMyW0GQR1XS
BC-3MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHvSVFKSzVyPUG1MlM6QCEQvF2=NEn4V5BUSU6JRWK=
BOKUNGLybZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTuWmg{UUN3ME2xOU46PjB6IN88US=>NU\TPZQ3W0GQR1XS
GOTOMom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvrfG9KSzVyPUG2Mlk3OTdizszNNX7Od4ZqW0GQR1XS
HCC2157Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTF5LkS3OVUh|ryPNHj0WZNUSU6JRWK=
LS-1034NVv0Z2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jnWGlEPTB;MUeuOlgyQCEQvF2=NGHOZpJUSU6JRWK=
CAL-148M1TtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEC0[3JKSzVyPUG3Mlk4QTZizszNMmHpV2FPT0WU
MOLT-4MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTCZ201UUN3ME2xPE45OjB6IN88US=>NX30VFFLW0GQR1XS
DaudiMnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTF6LkmyN|Eh|ryPMUPTRW5ITVJ?
J-RT3-T3-5NHLn[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DMemlEPTB;MUmuOFA3PiEQvF2=M1:2TnNCVkeHUh?=
KMOE-2NGTG[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrBTWM2OD1zOT62OFgzKM7:TR?=M13rN3NCVkeHUh?=
HL-60MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXKTWM2OD1{MD6xPVY2KM7:TR?=MoDhV2FPT0WU
P31-FUJNI[xbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXRTWM2OD1{MD60O|U{KM7:TR?=NHWy[m1USU6JRWK=
IM-9NV\JWlhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2W1NWlEPTB;MkCuOlIzPCEQvF2=MULTRW5ITVJ?
HDLM-2Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTJyLki4NlEh|ryPNH33XmpUSU6JRWK=
NCI-H1304Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTJzLkCzNVEh|ryPNHTSXXBUSU6JRWK=
NCI-H345NF\wXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7LZYl5UUN3ME2yNU4xPjR|IN88US=>NEjYR|RUSU6JRWK=
RPMI-6666NHL6cllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7rTWM2OD1{MT6zOlAzKM7:TR?=M1G1WXNCVkeHUh?=
GR-STNInKV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1m0ZWlEPTB;MkGuOFE4KM7:TR?=Mm\aV2FPT0WU
CHP-126M1XyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vTR2lEPTB;MkGuOlE5OSEQvF2=MWjTRW5ITVJ?
EHEBNWjBdpdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXJTWM2OD1{MT62O|MyKM7:TR?=NFPUfJBUSU6JRWK=
CPC-NMmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TTSGlEPTB;MkSuNFIxOSEQvF2=M33jUXNCVkeHUh?=
NB1NFLZSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjRe2tKSzVyPUK0MlY6OzlizszNM3\wOHNCVkeHUh?=
LS-123NUPWToo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\oU|BKSzVyPUK0MlkxOTJizszNM3HsfXNCVkeHUh?=
ST486NVzDWFBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoSxTWM2OD1{NT6xNVE{KM7:TR?=M17mPHNCVkeHUh?=
NCI-H1963M33pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnGNWJKSzVyPUK2MlA3OjNizszNNX7OOGZOW0GQR1XS
U-87-MGNWPONmZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHi4b2FKSzVyPUK2Mlc3PDRizszNM1;pcHNCVkeHUh?=
COR-L279NEGwT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTJ4Lke5NlIh|ryPNFy5SHFUSU6JRWK=
LU-165NXnSZ|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LB[mlEPTB;MkiuNFg3OSEQvF2=NGXQT3lUSU6JRWK=
COLO-800NUeyVmlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;vNWlEPTB;MkiuNlk2PiEQvF2=MWrTRW5ITVJ?
ETK-1NF3KfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7BPIFIUUN3ME2yPE4{PDR4IN88US=>Mn20V2FPT0WU
LNCaP-Clone-FGCM33uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrnN4ZDUUN3ME2yPU46OjhzIN88US=>M{fFfnNCVkeHUh?=
SIG-M5M1vjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XlVmlEPTB;M{CuO|k2OiEQvF2=NXyxUWJ5W0GQR1XS
NB6MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzGTWM2OD1|MD65OVA{KM7:TR?=Mmf2V2FPT0WU
NCI-H2107M{XyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTNzLkKzN|gh|ryPNYLkZY1MW0GQR1XS
SNU-C1MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rEWWlEPTB;M{GuN|EzPiEQvF2=NHTPNW1USU6JRWK=
JARM2LXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTNzLkO3PVkh|ryPNVqwSYszW0GQR1XS
L-363M4XEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\MTWM2OD1|Mj6yNVQ1KM7:TR?=NFj2VYRUSU6JRWK=
EW-24NI\QT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTN{LkO0O|Qh|ryPMkjtV2FPT0WU
NB69MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTN|Lk[0OVQh|ryPM4XnSnNCVkeHUh?=
EW-13Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTvTWM2OD1|Mz64PVY6KM7:TR?=M4LWPHNCVkeHUh?=
Ramos-2G6-4C10M1XyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIi4cXhKSzVyPUO0MlI6QTNizszNNIPFW2RUSU6JRWK=
TE-11M1TuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTN2LkS4NlIh|ryPM3vjVnNCVkeHUh?=
L-428NGHNZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnnWpM1UUN3ME2zOE44PTN4IN88US=>NVW0fodnW0GQR1XS
KP-N-YNNFzpfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HUbGlEPTB;M{SuPVA2PyEQvF2=NYXWfYFyW0GQR1XS
CGTH-W-1NFvJ[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPGTWM2OD1|Nj65NFQ5KM7:TR?=NXHTTIU3W0GQR1XS
K-562MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTN5LkC4OlQh|ryPNUHTb3NuW0GQR1XS
NCI-H1299NHXmclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2O1R2lEPTB;M{iuNVYxOyEQvF2=M1jNOHNCVkeHUh?=
RCC10RGBNHfNfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInrcIdKSzVyPUO4MlIxQDNizszNNFjRXXhUSU6JRWK=
NCI-SNU-16M4nJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkj6TWM2OD1|OD61OlU{KM7:TR?=Mk\lV2FPT0WU
LC-2-adMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTWXFVrUUN3ME2zPU41OzN5IN88US=>MkDuV2FPT0WU
MHH-PREB-1MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjrXHBKSzVyPUO5Mlc{QDhizszNM33QbHNCVkeHUh?=
NCI-H64NYjMPJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PSNWlEPTB;NECuNFk1QCEQvF2=NF61WWpUSU6JRWK=
LB996-RCCNWfJWVJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTRyLki3NVYh|ryPNEHXdWNUSU6JRWK=
DELMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrO[3k3UUN3ME20NU41PDB3IN88US=>NEDmVmZUSU6JRWK=
MLMAM2PVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTRzLke1PVUh|ryPMWfTRW5ITVJ?
SBC-1NY\ZT3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3Qb5FKSzVyPUSyMlE5ODZizszNNW\VemVlW0GQR1XS
MPP-89M2S3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWGyPZBsUUN3ME20Nk42QDd3IN88US=>NH7L[HpUSU6JRWK=
MV-4-11M3;vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorWTWM2OD12Mj65NFY4KM7:TR?=M133eHNCVkeHUh?=
EoL-1-NYD1S4xXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXQTWM2OD12ND6xOVY5KM7:TR?=NH\tSnZUSU6JRWK=
CW-2NFjyd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\nVW9KSzVyPUS0Mlg{PDJizszNNF7pU4RUSU6JRWK=
HTMoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILQOpRKSzVyPUS1MlcxODdizszNNHXCcVZUSU6JRWK=
SW954Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTR5LkSxNlgh|ryPNGPUSnBUSU6JRWK=
A3-KAWMni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETKVJNKSzVyPUS5MlgxPjFizszNM{XtO3NCVkeHUh?=
TC-YIKNYfrbJptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTVyLkCzOlMh|ryPNXq3eY84W0GQR1XS
SW962MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrpTHRKSzVyPUW0Mlg{PTdizszNMn60V2FPT0WU
KP-N-RT-BM-1Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLoSZVnUUN3ME21Ok43PjN6IN88US=>MXrTRW5ITVJ?
NCI-H1395MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTV6LkixO|Ih|ryPNIO1[IFUSU6JRWK=
RPMI-8402MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfiTFFKSzVyPUW4Mlk2OjZizszNNUjWWGJrW0GQR1XS
SCHMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTZyLkm2N|gh|ryPMV7TRW5ITVJ?
NCI-H2196MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7SUWNbUUN3ME22NU4zOzFizszNMoDhV2FPT0WU
LOXIMVIMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTZzLkiyOlYh|ryPMmfpV2FPT0WU
TGBC24TKBMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3CTFZKSzVyPU[yMlE1QTFizszNNGTtfGJUSU6JRWK=
SK-MEL-2NWXHc2tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlK1TWM2OD14Mz65PFkzKM7:TR?=MWLTRW5ITVJ?
U-698-MNFqzRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3qTYFKSzVyPU[4MlU3QDdizszNM{Tl[HNCVkeHUh?=
NCI-H1522NWjPNWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITHOIxKSzVyPU[5MlAxPDdizszNM2rGdnNCVkeHUh?=
UACC-812NWDM[ItZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7ibHVKSzVyPU[5MlUzODlizszNNF7sTpVUSU6JRWK=
MHH-CALL-2M2XtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTdyLkC2JO69VQ>?NYiwT4R4W0GQR1XS
NB5NUjPSHRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jtdWlEPTB;N{CuN|Q3QCEQvF2=NYW5NoxLW0GQR1XS
KARPAS-299M3HI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX74UVR3UUN3ME23NE41PDR5IN88US=>M4HJZnNCVkeHUh?=
NCI-H1694MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2qycWlEPTB;N{GuNFMzKM7:TR?=MmPrV2FPT0WU
NCI-H82M{LPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTdzLkm1NFch|ryPNHq1S4NUSU6JRWK=
SCC-15Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrDTWM2OD15Mj6zOEDPxE1?NXLY[|RVW0GQR1XS
NCI-H1436M4LxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXQbJFYUUN3ME23Nk44PDV4IN88US=>MoTwV2FPT0WU
ATN-1MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTd2LkWwOUDPxE1?NX3y[FdKW0GQR1XS
RPMI-8866MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTqTWM2OD15ND63OVA6KM7:TR?=NFn6dnVUSU6JRWK=
HCC1599NFT6TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDWfJVKSzVyPUe0Mlg4OzJizszNMWfTRW5ITVJ?
NCI-H1155MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;xTWM2OD15ND65N|Y4KM7:TR?=M3fYfHNCVkeHUh?=
DOHH-2NWHaUYhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjGc4llUUN3ME23OE46PTF2IN88US=>NH7Ke|RUSU6JRWK=
SK-NEP-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jNOmlEPTB;N{WuNFc2PCEQvF2=NIrId|BUSU6JRWK=
HCC1187MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7ESlh7UUN3ME23O{43OTJ{IN88US=>NXjVcHBHW0GQR1XS
NCI-H322MNFvlXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvvUWc6UUN3ME23PE4{PzB7IN88US=>M3XEZnNCVkeHUh?=
NCI-H526M3WwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XwbGlEPTB;N{iuOVg4PyEQvF2=MYrTRW5ITVJ?
NCI-H2171MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrrXFRNUUN3ME23PU41OTN4IN88US=>MnTUV2FPT0WU
COLO-668MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLRUmFKSzVyPUixMlU5QDRizszNMoTZV2FPT0WU
RS4-11NX32WHN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjCXVhKSzVyPUiyMlI2ODVizszNMULTRW5ITVJ?
NCI-H716NHraNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjOOVhKSzVyPUiyMlkxPzVizszNMW\TRW5ITVJ?
LU-134-ANWrNdXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkP5TWM2OD16Mz6xN|UyKM7:TR?=M1rCd3NCVkeHUh?=
RPMI-8226NFu2bmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjYOmRKSzVyPUi0MlIyODdizszNMk[zV2FPT0WU
KY821MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTlzLk[1OVEh|ryPNH;yVIZUSU6JRWK=
ECC4NE\WNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTl|LkiyOlkh|ryPNYDOe5pmW0GQR1XS
EW-3NVPkSll6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LWd2lEPTB;OUSuPVA5OSEQvF2=NV[xZ2hmW0GQR1XS
NB7NXnUWmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvvSIp5UUN3ME25OU44Pzh4IN88US=>MnrNV2FPT0WU
NCI-H720MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moj5TWM2OD17OD60NFYyKM7:TR?=M37Hd3NCVkeHUh?=
NCI-H446MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nSZmlEPTB;OUmuO|U5QCEQvF2=MV;TRW5ITVJ?
NCI-H889MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nhS2lEPTB;MUC0MlI1OiEQvF2=M4XqXHNCVkeHUh?=
EW-22MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4e0RmlEPTB;MUC2MlE6KM7:TR?=MXzTRW5ITVJ?
BV-173NFPZdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrHV4ZKSzVyPUGwPE44OjhizszNMVnTRW5ITVJ?
WSU-NHLNWThOI5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWL3dGNLUUN3ME2xNFkvPjdzIN88US=>M{DaPXNCVkeHUh?=
MN-60MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFyOT62PUDPxE1?M3vTcHNCVkeHUh?=
DG-75M{LqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3njS2lEPTB;MUGzMlM2OiEQvF2=NX3oZ3BJW0GQR1XS
DMS-79NH63SWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXmeW9XUUN3ME2xNVcvOzh{IN88US=>M2m4PHNCVkeHUh?=
SK-MEL-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2naZmlEPTB;MUG4MlAxQSEQvF2=NHztNnhUSU6JRWK=
DMS-153M2fDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnVUGxpUUN3ME2xNlEvPzR3IN88US=>MV7TRW5ITVJ?
NCI-H510ANInBboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zVVWlEPTB;MUK3MlMzKM7:TR?=NWXs[oxuW0GQR1XS
BE-13MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\MTWM2OD1zM{SuNFQ1KM7:TR?=MUXTRW5ITVJ?
KP-N-YSNIHmS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvFN|dKSzVyPUGzPU44OzZizszNMn\3V2FPT0WU
SUP-T1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTF2Mz63NFgh|ryPM2HGVHNCVkeHUh?=
EW-12MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\teGlEPTB;MUS0MlY6QSEQvF2=M2H0ZnNCVkeHUh?=
NB14NV3OPFlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HNXmlEPTB;MUS3MlA5OiEQvF2=NF\DfXpUSU6JRWK=
MDA-MB-134-VINGHPUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTF2OD6yOlgh|ryPNImzNnZUSU6JRWK=
NCI-H1770NY\CTI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTF3Nj6yO|kh|ryPNI\ERnFUSU6JRWK=
TURNYnVOVFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWq5TVhYUUN3ME2xOlcvQDdizszNMXvTRW5ITVJ?
NCI-H1417NWjPfmtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHNZY4zUUN3ME2xPFAvOzNzIN88US=>MlfvV2FPT0WU
IMR-5NHPoe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXLTWM2OD1zOEGuOVcyKM7:TR?=NXL0dJJ{W0GQR1XS
NCI-H226NUjyOJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TRWWlEPTB;MUi4Mlg3PiEQvF2=Mn[wV2FPT0WU
NCI-H187NEfiZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELjdpJKSzVyPUG5NE4xPjRizszNNVHxW4Z{W0GQR1XS
SF539M3S2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXOTWM2OD1zOUKuO|I5KM7:TR?=MmXwV2FPT0WU
TALL-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF7OD6zNFQh|ryPNULzNo5QW0GQR1XS
TE-441-TNGTZVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlO5TWM2OD1zOUmuO|M6KM7:TR?=MUDTRW5ITVJ?
REHM2XRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fWN2lEPTB;MkO2MlYzPiEQvF2=MXnTRW5ITVJ?
MS-1M4qyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTJ|OT6xNlEh|ryPNEDUSnZUSU6JRWK=
THP-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;kTWM2OD1{NkSuO|M5KM7:TR?=NXPBSINjW0GQR1XS
NCI-H1838NFew[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33DcGlEPTB;MkexMlQ2PiEQvF2=MoXxV2FPT0WU
P30-OHKM{PoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LFfWlEPTB;MkizMlg1PyEQvF2=M{KyRnNCVkeHUh?=
C8166MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LDWGlEPTB;M{S1MlM{QCEQvF2=MnLYV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Customer Product Validation(9)


Click to enlarge
Rating
Source Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us